Equity Overview
Price & Market Data
Price: $1.35
Daily Change: -$0.05 / 3.70%
Daily Range: $1.35 - $1.47
Market Cap: $86,014,224
Daily Volume: 318,619
Performance Metrics
1 Week: 1.43%
1 Month: 13.60%
3 Months: 42.53%
6 Months: -7.79%
1 Year: -49.82%
YTD: -17.44%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.